Preserving Patient Access to Home Infusion Act
Summary
The Preserving Patient Access to Home Infusion Act (S.1058) expands Medicare Part B coverage for home infusion therapy, explicitly including pharmacy services and non-pump drugs, and removes the physical presence requirement for per-day payment. This structurally raises addressable revenue for CVS Health's Coram and UnitedHealth Group's Optum infusion businesses. Both stocks show strong momentum — CVS up 15.75% and UNH up 34.54% over 30 days — though the bill is at early legislative stage (referred to committee).
See which stocks are affected
Key takeaways, market implications, full AI analysis, and connected signals are available to HillSignal members.
Already have an account? Log in
Key Takeaways
- 1.S.1058 expands Medicare home infusion coverage to include pharmacy services and non-pump drugs, directly benefiting CVS/Coram and UNH/Optum infusion businesses.
- 2.The bill removes the physical presence requirement for per-day payment and establishes a 5-hour infusion day payment floor (2026-2030), structurally raising per-patient reimbursement.
- 3.Early-stage bipartisan bill with companion House legislation; no hearings scheduled yet, but the transitional rule start date (Jan 2026) suggests sponsors target passage within 12-18 months.
Market Implications
CVS Health ($83.13) and UnitedHealth Group ($364.05) are the two publicly traded companies most directly positioned to benefit from expanded Medicare home infusion coverage. CVS's Coram is the market leader in home infusion, and Optum Infusion Services is the second-largest national provider. The 30-day momentum in both stocks (CVS +15.75%, UNH +34.54%) partly reflects broader healthcare sector rotation, but this bill adds a specific structural revenue tailwind. At current prices, both are near 52-week highs. The legislative risk is that the bill stalls in committee or is amended substantively, but bipartisan sponsorship and the companion House bill reduce that probability. Investors should monitor the Senate Finance Committee schedule for markups.
Full Analysis
-
What happened: On March 13, 2025, Sen. Warner (D-VA) and cosponsor Sen. Scott (R-SC) introduced S.1058, the Preserving Patient Access to Home Infusion Act. The bill was read twice and referred to the Senate Finance Committee. It remains at early legislative stage with only a single committee referral and no hearings scheduled yet. A companion bill (HR2172) exists in the House.
-
The money trail: This is an authorization bill — it changes the definition of covered home infusion therapy under Medicare Part B (Section 1861(iii)(2) and changes payment rules under Section 1834(u)(1)(A)). No specific dollar amount is authorized or appropriated. The mechanism is regulatory: CMS is directed to include pharmacy services in the home infusion benefit bundle, remove the physical presence requirement for per-day payment, and apply a temporary (2026-2030) 5-hour infusion day payment floor. These changes expand the scope of what Medicare pays for and increase per-day reimbursement rates. Actual spending depends on Medicare utilization; CMS would need to issue a rulemaking to implement payment rates.
-
Structural winners: The direct beneficiaries are companies with substantial Medicare home infusion operations. CVS Health (CVS) through Coram — the largest standalone home infusion provider in the US. UnitedHealth Group (UNH) through Optum Infusion Services — Optum's home infusion business operates in 48 states. Both companies benefit from: (a) new revenue from pharmacy service fees, (b) elimination of unbillable days due to physical presence rules, and (c) higher per-day reimbursement during the transitional 5-hour payment floor period. Smaller independent home infusion providers would also benefit but are not publicly traded pure-plays.
-
Real market data: CVS closed at $83.13 on 4/30/26, up 15.75% over 30 days and +6.66% over 7 days. UNH closed at $364.05, up 34.54% over 30 days and +2.57% over 7 days. Both stocks are near their 52-week highs (CVS: $85.15, UNH: $411.99). The 30-day momentum in both names reflects broader sector strength in managed care and pharmacy services, not solely this bill's prospects — but the bill's expansion of Medicare home infusion coverage adds a positive structural tailwind for these specific business lines.
-
Timeline: The bill is early stage — referred to Finance Committee with no hearings yet. The transitional payment rule (5-hour infusion day) would apply from Jan 1, 2026 to Jan 1, 2030, suggesting the bill's sponsors anticipate passage by end of 2025. Bipartisan sponsorship (Warner-D, Scott-R) and the companion House bill (HR2172) improve passage odds, but the legislative calendar for 2025-2026 includes competing priorities (drug pricing, ACA subsidies, government funding). Likely outcome: committee markup in late 2025, potential floor vote in 2026.
Intelligence Surface
Cross-referenced against federal contracts, SEC insider filings & congressional trade disclosures
Some confirming evidence found across public data sources
What the bill does
Medicare coverage expansion: the bill explicitly includes pharmacy services and non-pump infusion drugs under home infusion therapy, and removes the requirement for a qualified supplier to be physically present for payment to be made on a per-day basis.
Who must act
Centers for Medicare & Medicaid Services (CMS) — must revise Medicare Part B payment rules for home infusion therapy to cover pharmacy services and non-pump drug administration days regardless of physical presence.
What happens
CMS will reimburse CVS Health's Coram home infusion business for an additional revenue stream (pharmacy services) and for drug administration days that previously did not qualify for payment because a supplier was not physically present in the home. The transitional rule (2026-2030) also guarantees payment based on 5 hours of infusion per day, increasing per-day reimbursement rates for therapies that previously may have been reimbursed for fewer hours.
Stock impact
CVS Health's Coram division is one of the largest home infusion providers in the US. Expanding Medicare Part B coverage directly increases addressable revenue for Coram by adding pharmacy service fees and eliminating the physical presence barrier that previously left many administration days unbillable. Coram operates within CVS's Health Services segment (~40% of CVS revenue), and this bill structurally raises the revenue ceiling for that portion of the business.
What the bill does
Same as above — Medicare coverage expansion for pharmacy services and non-pump infusion drugs, with revised payment rules removing the physical presence requirement and establishing a 5-hour infusion day payment floor (2026-2030).
Who must act
Centers for Medicare & Medicaid Services (CMS) — must revise Medicare Part B payment rules for home infusion therapy.
What happens
CMS will reimburse Optum's home infusion business for pharmacy services and for previously unbillable administration days (when a supplier was not physically present). The 5-hour infusion day payment floor increases per-day reimbursement for certain therapies.
Stock impact
UnitedHealth Group's Optum division operates a large home infusion business through Optum Infusion Services. Expanded Medicare coverage directly increases Optum's addressable revenue from pharmacy services and eliminates the physical presence reimbursement barrier. Optum contributes ~45% of UNH's total revenue, and home infusion is a growing sub-segment within Optum's Care Delivery arm. The bill structurally increases the per-patient revenue opportunity from Medicare home infusion patients.
Connected Signals
Matched on shared policy language across AI analyses, with ticker & timing weight
Consolidated Appropriations Act, 2026
Protecting Health Care and Lowering Costs Act of 2025
To amend title XVIII of the Social Security Act to ensure stability for provider payments under the Medicare program.
TRIWEST HEALTHCARE ALLIANCE CORP: $820M Department of Veterans Affairs Contract
Association Health Plans Act
Protecting Health Care and Lowering Costs Act
Living Donor Protection Act of 2025
I CAN Act
Related Presidential Actions
Executive orders & memoranda affecting the same sectors or companies
Implementing Schedule Policy/Career in the Excepted Service
This executive order expands the Schedule Policy/Career excepted service category, transferring certain federal positions from competitive service to at-will employment to facilitate removal for poor performance or misconduct. It directs agency heads to petition for reclassification of policy-influencing roles, mandates performance bonus pools for these employees, and amends civil service rules to exempt them from standard adverse action procedures.
Realigning United States Core Childhood Vaccine Recommendations with Best Practices from Peer, Developed Countries
This executive order directs the CDC and ACIP to review and potentially update the U.S. childhood vaccine schedule to align with recommendations from peer developed countries, which recommend fewer vaccines. It maintains insurance coverage for all currently available vaccines without cost sharing and emphasizes protecting religious liberty and parental authority.
Promoting Efficiency, Accountability, and Performance in Federal Contracting
This executive order mandates that federal agencies default to using fixed-price contracts for procurement, shifting away from cost-reimbursement models. It requires written justification and senior-level approval for any non-fixed-price contract over certain dollar thresholds (e.g., $10M for most agencies, $100M for the Department of War), and directs agencies to review and renegotiate their 10 largest non-fixed-price contracts within 90 days. The order also tasks OMB with implementation guidance and the Federal Acquisition Regulatory Council with proposing regulatory amendments within 120 days.
Free — no credit card
Get the next market-moving signal before the news does
HillSignal scores every Congressional bill, federal contract, and insider filing for market impact and emails you the high-conviction ones — free, no credit card.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →